Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Here's Why You Should Hold On To LabCorp (LH) Stock For Now

By Zacks Investment ResearchStock MarketsMar 26, 2020 09:02PM ET
www.investing.com/analysis/heres-why-you-should-hold-on-to-labcorp-lh-stock-for-now-200519574
Here's Why You Should Hold On To LabCorp (LH) Stock For Now
By Zacks Investment Research   |  Mar 26, 2020 09:02PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Laboratory Corporation of America Holdings (NYSE:LH) or LabCorp has been gaining from both of its operating segments domestically. The company’s increasing number of acquisitions, a favorable mix and current initiatives buoy optimism. However, price reductions due to the Protecting Access to Medicare Act (PAMA) and the loss of exclusivity in two managed-care contracts are downsides.

Over the past year, shares of the Zacks Rank #3 (Hold) company have lost 9% compared with the industry’s 21.7% decline.

The renowned healthcare diagnostics company, offering comprehensive clinical laboratory services and end-to-end drug development support providers, has a market capitalization of $13.34 billion. The company projects 6.7% growth for the next five years and expects to maintain its strong performance. Further, it delivered a positive earnings surprise of 2.2%, on average, over the trailing four quarters.


Let’s delve deeper.

Impressive Q4 Results: We are upbeat about the company’s fourth-quarter performance, where it reported better-than-expected results. It exhibited strong underlying and organic growth across its Diagnostics and Drug Development businesses on the solid execution of its three fundamental strategies. In the quarter, LabCorp also witnessed solid contributions from acquisitions. Further, its Diagnostics segment witnessed a solid rise in total volume (measured by requisition) and improvement in revenue per requisition in the fourth quarter.

The company is also on track with its Diagnostics and the Covance LaunchPad initiatives. The expansion of both margins further buoys optimism.

Contributions to Combat Coronavirus Outbreak: We are optimistic about LabCorp’s efforts to contain the global coronavirus outbreak. In early March, the company launched the 2019 Novel Coronavirus (COVID-19), NAA test for physicians and other authorized healthcare providers across the United States. Later, LabCorp confirmed that it reached the capability of performing more than 20,000 coronavirus tests per day, representing a significant increase in its capacity since the release of the test.

Further, LabCorp plans to explore all possible options to prioritize coronavirus testing for the hospital inpatient population, which includes patients currently being treated for suspected coronavirus infection, uplifts our sentiment.

Covance Drug Development (CDD) Expands: We are upbeat about the company’s progress in its CDD segment. LabCorp is enhancing the segment's offerings through acquisitions like that of MI Bioresearch, which is expected to create an opportunity for the CDD segment to move from preclinical to clinical development. We are also optimistic about the company’s plans to acquire Regulatory and Clinical Research Institute, a device-focused contract research organization that has strong regulatory consulting expertise.

Downsides

Adverse Impact of Reimbursement Cut: Changes in governmental regulations significantly affected LabCorp’s operations, especially in the last couple of years, where it faced several reimbursement issues that hurt its revenues. The company is concerned about the Centers for Medicare & Medicaid Services’ latest Medicare reimbursement reduction as a result of the implementation of PAMA.

Stiff Competition: LabCorp competes with biggies like Quest Diagnostics (NYSE:DGX) as well as other commercial laboratories and hospitals. While pricing is an important factor in choosing a testing lab, hospital-affiliated physicians expect a high level of service. As a result, LabCorp and other commercial labs compete with hospital-affiliated labs primarily based on the quality of service.

Estimate Trend

The company is witnessing a positive estimate revision trend for 2020. Over the past 60 days, the Zacks Consensus Estimate for its earnings has moved 3.7% north to $2.81.

The Zacks Consensus Estimate for LabCorp’s first-quarter 2020 revenues is pegged at $2.95 billion, suggesting a 5.6% rise from the year-ago reported number.

Key Picks

Some better-ranked stocks from the broader medical space are ResMed Inc. (NYSE:RMD) , Medtronic plc (NYSE:MDT) and QIAGEN N.V. (NYSE:QGEN) .

ResMed has a projected long-term earnings growth rate of 14.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Medtronic’s long-term earnings growth rate is estimated at 7.1%. The company presently carries a Zacks Rank #2.

QIAGEN’s long-term earnings growth rate is estimated at 10%. It currently carries a Zacks Rank #2.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Medtronic PLC (MDT): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

QIAGEN N.V. (QGEN): Free Stock Analysis Report

Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

Original post

Zacks Investment Research
Here's Why You Should Hold On To LabCorp (LH) Stock For Now
 

Related Articles

Here's Why You Should Hold On To LabCorp (LH) Stock For Now

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email